Pfizer is a global pharmaceutical company and among the top pharmaceutical companies in the world. Pfizer is headquartered in New York City. In 2024, the company's total revenue stood at **** billion U.S. dollars. Pfizer’s global positioning Pfizer’s products are available in many countries worldwide and as of 2024, the company had more than *** research and development projects in the pipeline. For several years, Pfizer was the top pharmaceutical company based on global prescription drug sales and is among the leading pharmaceutical companies based on research and development (R&D) spending. Pfizer’s largest segment is Innovative Health (IH). The Innovative Health business focuses on various rare diseases, vaccines, immunology and internal medicine to name a few. Pfizer’s top products In 2024, products from the Prevnar family were among Pfizer's top products based on revenue. However, Pfizer has several other drugs that are also well-known. For example, Lipitor (atorvastatin calcium) is used in the treatment of high cholesterol. Over the years, however, Lipitor revenues have been on the decline due to patent loss, yet it remains part of Pfizer’s top products. One of Pfizer’s most well-known products, Viagra (sildenafil citrate), used in the treatment of erectile disfunction, has also been on the decline with 2019 having the lowest revenues on record. The low revenues are mainly attributable to Viagra’s loss of patent exclusivity in the U.S. in December 2017.

Pfizer's annual revenue was $63.63 B in fiscal year 2024. The annual revenue increased $4.07 B from $59.55 B (in 2023) to $63.63 B (in 2024), representing a 6.84% year-over-year growth.

In 2024, Pfizer generated total revenues of some **** billion U.S. dollars. For Q1, 2025, the company reported revenues of some **** billion U.S. dollars. That was significantly lower than in the same quarter in 2024. By failing to prepare, you are preparing to fail The majority of Pfizer’s revenue comes from the manufacture and sale of its products. Pharmaceutical companies are always planning for the future, looking for ways to offset the impact felt when those products start to lose market exclusivity. The development of products is essential for the continued growth of the company, and investing in research and development (R&D) is one way of identifying new, innovative medicines. Pfizer’s R&D expenditure stood at around **** billion U.S. dollars in 2024. Why Pfizer’s revenues decreased until 2020? Pfizer averaged quarterly revenues of around **** billion U.S. dollars in the four years from the start of 2016 to the end of 2019 – this is considerably lower than the **** billion U.S. dollars the company averaged per quarter in 2010. One reason for the decline was competition from generic drugs that entered the market when key patents expired. Pfizer lost the market exclusivity for its Lipitor product at the end of 2011, and revenues were greatly affected as a consequence. Additionally, following a review of its product portfolio, Pfizer’s revenues were also impacted by the decision to spin off some of its business segments, such as its animal health division in 2013 and its Upjohn business in 2020.

Sales from the United States contributed more than 38 billion U.S. dollars towards Pfizer's total revenue of around 63.6 billion U.S. dollars in 2023. Pfizer sees strong growth in emerging markets Pfizer’s total revenue is divided into four geographic areas: the United States, Developed Markets, and Emerging Markets. China is one of the company’s largest single markets behind the United States, which contributed 60 percent of Pfizer’s total revenue. Pfizer continues to support investment in emerging markets, but the vulnerable nature of these countries means strategies come with an element of risk due to unforeseen financial or political events, for example. The power of product patents Managing the expiration of key patents is one of the greatest challenges facing Pfizer because competition from generic versions can make a big difference to company revenues. Many of Pfizer’s leading products enjoy the security of market exclusivity, but less expensive generic versions are free to enter the market when these property rights end. In 2019, Pfizer anticipated a fall in sales revenue from China due to significant competition from generic versions.

"PFIZER H.C.P. CORPORATION" atstovybė financial data: profit, annual turnover, paid taxes, sales revenue, equity, assets (long-term and short-term), profitability indicators.

The net income of Pfizer stood at some ***** billion U.S. dollars in 2024. In the preceding year, the net income was at over *** billion U.S. dollars. What factors affect net income? Companies discover how much they have earned or lost during an accounting period by analyzing their net income. For example, rising costs are among several reasons for the significant fall in Pfizer’s net income in 2020: the company increased its research and development expenditure, and suffered additional costs associated with the restructuring of the organization. It is worth adding that the high net income in 2017 was favorably impacted by a tax benefit of around **** billion U.S. dollars. The pros and cons of mergers and acquisitions Mergers and acquisitions are a common business strategy used by companies looking to grow. ***** of the largest deals in pharmaceutical industry history involve Pfizer, including its acquisition of Warner-Lambert for a record fee of around ** billion U.S. dollars in 2000. Advantages of the tactic include a larger workforce, increased spending budgets, and breaking into new markets. However, a failure to anticipate potential problems can be damaging to a company. For instance, the integration may disrupt current business operations, and inconsistencies may start to appear in standards and procedures.

Pfizer's annual net income per employee was $99.01 K in fiscal year 2024. The net income per employeeincreased$74.77 Kfrom $24.24 K(in 2023) to $99.01 K (in 2024), representing a 308.49% year-over-year growth.

Get detailed Pfizer Financial Statements 2020-2024. Find the income statements, balance sheet, cashflow, profitability, and other key ratios.

"Pfizer Luxembourg SARL" filialas financial data: profit, annual turnover, paid taxes, sales revenue, equity, assets (long-term and short-term), profitability indicators.

United States US: PFE: Revenue (External): Essential Health Product: International: Developed Rest of World data was reported at 2,123,000.000 USD th in Sep 2018. This records an increase from the previous number of 1,402,000.000 USD th for Jun 2018. United States US: PFE: Revenue (External): Essential Health Product: International: Developed Rest of World data is updated quarterly, averaging 1,878,000.000 USD th from Jun 2015 (Median) to Sep 2018, with 14 observations. The data reached an all-time high of 3,343,000.000 USD th in Dec 2016 and a record low of 648,000.000 USD th in Mar 2018. United States US: PFE: Revenue (External): Essential Health Product: International: Developed Rest of World data remains active status in CEIC and is reported by Pfizer Incorporation. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Pfizer Incorporation (PFE): Financial Data Breakdowns & Operational Data.

United States US: PFE: Revenue (External): Innovative Health Product: International: Developed Rest of World data was reported at 1,753,000.000 USD th in Jun 2018. This records an increase from the previous number of 812,000.000 USD th for Mar 2018. United States US: PFE: Revenue (External): Innovative Health Product: International: Developed Rest of World data is updated quarterly, averaging 1,980,000.000 USD th from Sep 2014 (Median) to Jun 2018, with 16 observations. The data reached an all-time high of 3,433,000.000 USD th in Dec 2017 and a record low of 707,000.000 USD th in Mar 2015. United States US: PFE: Revenue (External): Innovative Health Product: International: Developed Rest of World data remains active status in CEIC and is reported by Pfizer Incorporation. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Pfizer Incorporation (PFE): Financial Data Breakdowns & Operational Data.

United States US: PFE: Revenue (External): Essential Health Product: International data was reported at 10,238,000.000 USD th in Sep 2018. This records an increase from the previous number of 6,891,000.000 USD th for Jun 2018. United States US: PFE: Revenue (External): Essential Health Product: International data is updated quarterly, averaging 8,591,500.000 USD th from Jun 2015 (Median) to Sep 2018, with 14 observations. The data reached an all-time high of 14,836,000.000 USD th in Dec 2015 and a record low of 3,220,000.000 USD th in Mar 2017. United States US: PFE: Revenue (External): Essential Health Product: International data remains active status in CEIC and is reported by Pfizer Incorporation. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Pfizer Incorporation (PFE): Financial Data Breakdowns & Operational Data.

This statistic depicts the annual sales percent change of the top pharmaceutical companies worldwide between 2021 and 2022. For U.S. company Pfizer, annual sales increased around ** percent between 2021 and 2022, still mostly boosted by the massive sales of its COVID-19 vaccine Comirnaty.

Financial overview and grant giving statistics of Pfizer, Inc.

The gross profit of Pfizer Limited with headquarters in India amounted to ***** billion Indian rupees in 2023. The reported fiscal year ends on March 31.Compared to the earliest depicted value from 2020 this is a total decrease by approximately **** billion Indian rupees. The trend from 2020 to 2023 shows, however, that this decrease did not happen continuously.

The liabilities of Pfizer with headquarters in the United States amounted to ***** billion U.S. dollars in 2024. The reported fiscal year ends on December 31.Compared to the earliest depicted value from 2020 this is a total increase by approximately ***** billion U.S. dollars. The trend from 2020 to 2024 shows, however, that this increase did not happen continuously.

United States US: PFE: Revenue (External): Essential Health Product: International: Developed EU data was reported at 2,340,000.000 USD th in Sep 2018. This records an increase from the previous number of 1,591,000.000 USD th for Jun 2018. United States US: PFE: Revenue (External): Essential Health Product: International: Developed EU data is updated quarterly, averaging 2,277,000.000 USD th from Jun 2015 (Median) to Sep 2018, with 14 observations. The data reached an all-time high of 4,442,000.000 USD th in Dec 2015 and a record low of 778,000.000 USD th in Mar 2018. United States US: PFE: Revenue (External): Essential Health Product: International: Developed EU data remains active status in CEIC and is reported by Pfizer Incorporation. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Pfizer Incorporation (PFE): Financial Data Breakdowns & Operational Data.

United States US: PFE: Revenue (External): Innovative Health Product: International data was reported at 6,982,000.000 USD th in Jun 2018. This records an increase from the previous number of 3,285,000.000 USD th for Mar 2018. United States US: PFE: Revenue (External): Innovative Health Product: International data is updated quarterly, averaging 7,974,500.000 USD th from Sep 2014 (Median) to Jun 2018, with 16 observations. The data reached an all-time high of 13,047,000.000 USD th in Dec 2014 and a record low of 2,767,000.000 USD th in Mar 2015. United States US: PFE: Revenue (External): Innovative Health Product: International data remains active status in CEIC and is reported by Pfizer Incorporation. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Pfizer Incorporation (PFE): Financial Data Breakdowns & Operational Data.

The net cash of Pfizer with headquarters in the United States amounted to ***** billion U.S. dollars in 2024. The reported fiscal year ends on December 31.Compared to the earliest depicted value from 2020 this is a total decrease by approximately **** billion U.S. dollars. The trend from 2020 to 2024 shows, however, that this decrease did not happen continuously.

United States US: PFE: Revenue (External): Essential Health Product: US data was reported at 4,859,000.000 USD th in Sep 2018. This records an increase from the previous number of 3,379,000.000 USD th for Jun 2018. United States US: PFE: Revenue (External): Essential Health Product: US data is updated quarterly, averaging 4,849,500.000 USD th from Jun 2015 (Median) to Sep 2018, with 14 observations. The data reached an all-time high of 9,596,000.000 USD th in Dec 2016 and a record low of 1,731,000.000 USD th in Mar 2018. United States US: PFE: Revenue (External): Essential Health Product: US data remains active status in CEIC and is reported by Pfizer Incorporation. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Pfizer Incorporation (PFE): Financial Data Breakdowns & Operational Data.